For three years, the binding constraint on GLP-1 medicine in America has not been science, or regulation, or even money. It has been the number of sterile injection devices that can be filled per hour on the planet.
That is a strange sentence to write about a class of drugs this consequential, and it explains almost everything about the shortages, the compounding boom, the telehealth industry, and the peculiar rationing decisions that followed.
Two very different kinds of drug
Semaglutide and tirzepatide are peptides — chains of amino acids. They are made biologically, purified, formulated as sterile injectables, and filled into single-use pens on equipment that is expensive, slow, and in global short supply. The manufacturers have committed billions to expanding that capacity and it has still not been enough.
Orforglipron is not a peptide. It is a small molecule that happens to activate the same receptor — the sort of thing the pharmaceutical industry has been making by the tonne since the 1950s. It does not need refrigeration in the same way, does not need a pen, does not need sterile fill-finish, and does not need to be taken on an empty stomach with the water and timing rules that make Rybelsus awkward to live with.
The interesting question about the pill is not “will I still have to inject.” It is “how many million more people can be supplied.”
What the efficacy trade looks like
The honest picture, so far, is that oral small-molecule agents land somewhere in the range the first generation of injectables occupied — meaningful weight loss, clearly better than placebo, and below what the best injectables achieve.
| Approximate mean weight reduction in pivotal trials | |
|---|---|
| Semaglutide 2.4 mg, 68 weeks | ~15% |
| Tirzepatide 15 mg, 72 weeks | ~21% |
| Retatrutide 12 mg, 48 weeks (phase 2) | ~24% |
| Oral small-molecule agents, reported to date | roughly 10–13% |
Those figures come from different trials, in different populations, over different durations, and they are averages with enormous individual spread. They are not a league table. But the shape of the trade-off is real: you give up some efficacy and you get a drug that can actually be manufactured for everyone who needs one.
Who a pill is actually for
Not, mostly, the people currently doing well on injections at a high dose. Those patients have found something that works and there is no reason to move them.
The people a pill changes things for are more specific:
- Anyone whose plan will not cover an injectable but might cover a cheaper oral option
- People with genuine needle phobia, which is more common and more disabling than it sounds
- Patients whose target is metabolic rather than cosmetic — modest, durable weight reduction to move blood pressure, A1c, or liver fat
- Everyone outside the wealthy world, where cold chain and device supply are the real barriers
- People who never started because the whole apparatus of pens, sharps and refrigeration felt like too much to take on
That last group is larger than the clinical literature has any way of measuring.
What I expect to go wrong
Two things.
The first is that launch pricing will disappoint people who assumed manufacturing cost has anything to do with US list price. It does not. A tablet that costs a dollar to make will be priced against what the market and the payers will bear, and the early period will be set by strategy rather than by chemistry. Cheaper drugs generally arrive later, once competition does.
The second is that the efficacy gap will be flattened in marketing until nobody can see it. A patient who would have lost twenty percent on tirzepatide, switched to a pill because it was easier to get approved, and who then loses eleven, has not been well served — even though eleven percent is a genuinely good clinical outcome. Both things are true, and the second one gets lost.
The only defence against that is knowing your own numbers before the switch. What you weighed, at what dose, on what date, and how the curve was behaving when somebody moved you. Without a baseline, a downgrade is indistinguishable from a plateau — which is precisely why anyone considering a change should have a few months of Zenday or an equivalent behind them first.
The larger point
We have spent three years treating GLP-1 access as a moral question — who deserves these drugs, who is taking the easy way out, who should be at the front of the queue. Much of that argument was downstream of scarcity, and much of the scarcity was a fill-finish problem.
Solve the manufacturing and a good deal of the moralising quietly loses its subject.